Maxigen Biotech Dividends and Buybacks

Dividend criteria checks 3/6

Maxigen Biotech is a dividend paying company with a current yield of 2.13% that is well covered by earnings.

Key information

2.1%

Dividend yield

-0.2%

Buyback Yield

Total Shareholder Yield1.9%
Future Dividend Yieldn/a
Dividend Growth3.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareNT$0.999
Payout ratio57%

Recent dividend and buyback updates

Recent updates

Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 20
Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, 1783 has been paying a dividend for less than 10 years.

Growing Dividend: 1783's dividend payments have increased, but the company has only paid a dividend for 7 years.


Dividend Yield vs Market

Maxigen Biotech Dividend Yield vs Market
How does 1783 dividend yield compare to the market?
SegmentDividend Yield
Company (1783)2.1%
Market Bottom 25% (TW)1.8%
Market Top 25% (TW)4.6%
Industry Average (Biotechs)2.5%
Analyst forecast (1783) (up to 3 years)n/a

Notable Dividend: 1783's dividend (2.13%) is higher than the bottom 25% of dividend payers in the TW market (1.8%).

High Dividend: 1783's dividend (2.13%) is low compared to the top 25% of dividend payers in the TW market (4.58%).


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (57.2%), 1783's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (36.2%), 1783's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Maxigen Biotech Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeCapital Securities Corporation
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Hsiu Chi LinMasterlink Securities Corp.